Rheumatoid Arthritis

Latest Headlines

Latest Headlines

Lilly and Incyte's oral arthritis drug aces its first Phase III test

A new rheumatoid arthritis pill from Eli Lilly and Incyte beat out placebo in a pivotal trial, the first late-stage success for a drug the companies hope can carve out a space in a crowded market.

J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III

Johnson & Johnson is walking away from a potential rheumatoid arthritis treatment from Astellas, nixing a deal that could have paid out at $945 million and putting the drug's stateside future in jeopardy.

J&J bets up to $277M on a prospect from its R&D farm system

Johnson & Johnson's plan to grow its pipeline with deal-scouting outposts around the globe is beginning to pay off, as the drugmaker's London lookout has brought in what could be a promising approach to rheumatoid arthritis.

Sanofi, UCB team up in $138M deal aimed at tackling biologic blockbusters

Sanofi is joining forces with UCB to study new small-molecule approaches to treating inflammatory conditions like arthritis, looking for an easier form of administration to some of the blockbuster injected biologics that dominate the field. The pharma giant is ready to spend more than $138 million for a package of milestones and an upfront payment to UCB in exchange for the partnering arrangement with its NewMedicines research arm.

Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug

Sanofi has experienced a series of internal setbacks on the R&D front in recent months, but its close partnership with Regeneron is still paying off with promising late-stage data. 

Bristol-Myers takes shot at Humira as arthritis drug aces Phase IIb

Bristol-Myers Squibb's little-discussed rheumatoid arthritis drug clazakizumab posted strong results in a mid-stage study, meeting its endpoints, notching promising remission data and stirring hopes that the treatment can compete with AbbVie's blockbuster Humira.

Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII

Isis Pharmaceuticals has opted to throw in the towel on its rheumatoid arthritis program for ISIS-CRP Rx, but the biotech says it will continue to plug away at studies of the antisense treatment for other diseases, including a mid-stage trial for atrial fibrillation due to read out next year.

Lilly's oral rheumatoid arthritis blockbuster contender champions 1-year study

Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.

AstraZeneca tosses another PhIII failure onto the scrap heap

AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to scrap its development efforts and turn the whole program back over to Rigel, the biotech partner which had licensed it to them in the first place

Europeans throw cold water on Pfizer's hot streak with Xeljanz rejection

European authorities have battered expectations for Pfizer's rheumatoid arthritis pill Xeljanz, spurning the drug giant's request for approval over concerns about the risk-benefit profile. The surprise rejection cools the company's run of regulatory success, which included 5 FDA approvals in 2012.